Chronic kidney disease

• Cardiovascular disease — also called heart disease — is a condition affecting the heart and blood vessels, and is the leading cause of death among women worldwide.
• In fact, a women dies of heart disease every 20 minutes in Canada.
• Although cardiovascular disease is often considered a disease of men, women are more likely to die from a heart attack when compared with men.

Women’s hearts are different

• From the outside, women’s hearts may look the same as men’s, but there are important differences.
• Specifically, women experience unique events over the course of their lifespan which may impact their cardiovascular health.
• Pregnancy complications, such as hypertensive disorders of pregnancy and gestational diabetes, can also play a role in cardiovascular health.

Heart attack symptoms

• Early heart attack symptoms are missed in up to 78 per cent of women, in part related to the fact that women may present with different symptoms than men.
• An awareness of the differences in heart attack symptoms may lead to improved recognition and timely care for women.

Reducing heart risks

• There are many steps that you can take to reduce your risk of heart disease.
• Living free from commercial tobacco and vaping, reducing alcohol intake and managing stress are also key ways to reduce your risk.

Wear red and learn more

• On Feb. 13, we invite you to celebrate Wear Red Canada to raise awareness for women’s cardiovascular health, hosted by the Canadian Women’s Heart Health Alliance and the Canadian Women’s Heart Health Centre.
• Attend free presentations and webinars by Canadian experts, join the Wear Red Canada Movement Challenge and take part in local events.

Nabilah Gulamhusein has received funding from the Canadian Institutes of Health Research through the Canada Graduate Scholarship - Master’s. Sandi Dumanski receives funding from the Canadian Fertility and Andrology Society and the Kidney Foundation.

• Saghmos Therapeutics, Inc. (Saghmos), a privately held biopharmaceutical company, announced a Notice of Allowance for a second US patent for its Phase 3-ready product, ST-62516 (trimetazidine), a cardiorenal metabolic modulator.
• "We are very pleased to announce the Notice of Allowance for our second patent, which will enhance the long-term value of ST-62516.
• Saghmos continues to build its intellectual property estate,” commented Anna Kazanchyan, MD, Founder and CEO of Saghmos Therapeutics.
• ST-62516 could benefit all PCI patients, not just those with comorbidities, to reduce the threat of AKI and MACKE after PCI.

• SierraConstellation Partners (“SCP”), a national interim management and advisory firm, has been awarded top industry accolades for the firm’s work on the restructuring of Tricida, Inc. (“Tricida”), a clinical-stage pharmaceutical company focused on the development and commercialization of a drug for the treatment of chronic kidney disease.
• SCP was brought in to work as a financial advisor to Tricida in November 2022.
• “We are honored to be recognized by multiple prestigious organizations for our work with Tricida,” said Larry Perkins.
• This recognition not only reflects our commitment to excellence but also underscores the dedication and hard work of the entire team.

• Winhealth Investment and VFMCRP entered into a License Agreement (the “License Agreement”) for the Product on 28 June 2023.
• Upon the expiration of the aforementioned term, the License Agreement may automatically be renewed for ten years as per certain conditions defined in the License Agreement.
• There is an issued patent that protects the formulation, usage, particle size and manufacturing methods of the Product in China.
• Velphoro® is a newly approved innovative drug in China in 2023 and has been successfully included in category B of the National Reimbursement Drug List.